These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 3814172)

  • 1. Delivery of 5-aminosalicylate to the guinea pig cecum.
    Salata K; Dull BJ; Goldman P
    Biochem Pharmacol; 1987 Jan; 36(2):295-7. PubMed ID: 3814172
    [No Abstract]   [Full Text] [Related]  

  • 2. Ex vivo evaluation of degradation rates of metronidazole and olsalazine in distal ileum and in cecum: The impact of prandial state.
    Karatza E; Goumas C; Muenster U; Reppas C; Vertzoni M
    Int J Pharm; 2017 Dec; 534(1-2):237-241. PubMed ID: 29030290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prophylactic effect of 5-aminosalicylic acid and salazosulphapyridine on degraded-carrageenan-induced colitis in guinea pigs.
    Jensen BH; Andersen JO; Poulsen SS; Skov Olsen P; Nørby Rasmussen S; Hansen SH; Hvidberg EF
    Scand J Gastroenterol; 1984 May; 19(3):299-303. PubMed ID: 6146186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract.
    Myers B; Evans DN; Rhodes J; Evans BK; Hughes BR; Lee MG; Richens A; Richards D
    Gut; 1987 Feb; 28(2):196-200. PubMed ID: 3557190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of food coadministration on 5-aminosalicylic acid oral suspension bioavailability.
    Yu DK; Elvin AT; Morrill B; Eichmeier LS; Lanman RC; Lanman MB; Giesing DH
    Clin Pharmacol Ther; 1990 Jul; 48(1):26-33. PubMed ID: 2369807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the intestinal flora in the acetylation of sulfasalazine metabolites.
    Dull BJ; Salata K; Goldman P
    Biochem Pharmacol; 1987 Nov; 36(21):3772-4. PubMed ID: 2890356
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of enteric bacteria in the anaerobic metabolism of 5-aminosalicylate.
    Tucker MA; Bisesi MS; Smith TJ
    J Biochem Toxicol; 1989; 4(4):267-8. PubMed ID: 2634099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Negligible excretion of 5-aminosalicylic acid in breast milk.
    Klotz U; Harings-Kaim A
    Lancet; 1993 Sep; 342(8871):618-9. PubMed ID: 8102746
    [No Abstract]   [Full Text] [Related]  

  • 9. Sulfasalazine and 5-ASA compounds.
    Allgayer H
    Gastroenterol Clin North Am; 1992 Sep; 21(3):643-58. PubMed ID: 1355468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aerobic biodegradation of 3-aminobenzoate by gram-negative bacteria involves intermediate formation of 5-aminosalicylate as ring-cleavage substrate.
    Russ R; Müller C; Knackmuss HJ; Stolz A
    FEMS Microbiol Lett; 1994 Sep; 122(1-2):137-43. PubMed ID: 7958765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refractory distal ulcerative colitis responsive to 5-aminosalicylate enemas.
    Barber GB; Lee DE; Antonioli DA; Peppercorn MA
    Am J Gastroenterol; 1985 Aug; 80(8):612-4. PubMed ID: 2862789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rate limiting steps in metabolite kinetics: formation of 5-acetylaminosalicylate after administration of 5-aminosalicylate.
    Houston JB; Cassidy MK
    J Pharm Pharmacol; 1982 Aug; 34(8):536-8. PubMed ID: 6126573
    [No Abstract]   [Full Text] [Related]  

  • 13. Will there be a next generation of sulfasalazine?
    Goldman P
    Gastroenterology; 1982 Nov; 83(5):1138-41. PubMed ID: 6126420
    [No Abstract]   [Full Text] [Related]  

  • 14. [Metabolism of PASA during administration of the preparation once and thrice daily].
    Savula MM
    Probl Tuberk; 1967; 45(4):70-4. PubMed ID: 5606807
    [No Abstract]   [Full Text] [Related]  

  • 15. [Is preventive drug therapy of recurrent Crohn disease indicated after ileocecal resection?].
    Koop I
    Internist (Berl); 1994 Feb; 35(2):192. PubMed ID: 7908661
    [No Abstract]   [Full Text] [Related]  

  • 16. Bioavailability studies on p-aminosalicylic acid and its various salts in man. II. Comparison of parasal and pascorbic.
    Pentikainen P; Wan SH; Azarnoff DL
    Am Rev Respir Dis; 1973 Dec; 108(6):1340-70. PubMed ID: 4751720
    [No Abstract]   [Full Text] [Related]  

  • 17. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans.
    Rasmussen SN; Bondesen S; Hvidberg EF; Hansen SH; Binder V; Halskov S; Flachs H
    Gastroenterology; 1982 Nov; 83(5):1062-70. PubMed ID: 7117789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics of 5-aminosalicylic acid after jejunal instillation in man.
    Haagen Nielsen O; Bondesen S
    Br J Clin Pharmacol; 1983 Dec; 16(6):738-40. PubMed ID: 6661362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The level of p-aminosalicyclic acid in the blood in oral treatment with a calcium-aluminum-p-aminosalicylate].
    Mulder RJ; Huizinga T
    Ned Tijdschr Geneeskd; 1968 Sep; 112(37):1630-4. PubMed ID: 4878452
    [No Abstract]   [Full Text] [Related]  

  • 20. A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics.
    Klotz U; Maier KE; Fischer C; Bauer KH
    Arzneimittelforschung; 1985; 35(3):636-9. PubMed ID: 4039590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.